<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1501">
  <stage>Registered</stage>
  <submitdate>17/12/2003</submitdate>
  <approvaldate>17/12/2003</approvaldate>
  <actrnumber>ACTRN12607000038493</actrnumber>
  <trial_identification>
    <studytitle>HABITS
Hormonal replacement therapy after breast cancer diagnosis - is it safe?</studytitle>
    <scientifictitle>Hormonal replacement therapy after breast cancer diagnosis - is it safe?
Protocol for randomized clinical study concerning hormonal replacement therapy (HRT) after previous radical breast cancer treatment</scientifictitle>
    <utrn />
    <trialacronym>IBCSG 17-98 / BIG 3-97 (HABITS)</trialacronym>
    <secondaryid>National Clinical Trials Registry: NCTR444</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Breast Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>HRT treatment shall aim at relieving vasomotor symptoms, and at the same time be well tolerated. The trial aims that investigating the effects of medium potency estrogen replacement (with or without progestins) therapy as it is commonly given in the environment where the patient lives and the clinician work. If there is no specific preference, the following is recommended:
1. Women with an intact uterus
a) Last menstrual bleeding, whether natural or caused by treatment, within two years: Cyclic combined estrogen-progestin combination (medium potency estrogen combined with a progestin, according to due treatment practice).
b) Last bleeding, two years or longer ago: Continuous combined estrogen-progestin combination ( medium potency
estrogen combined with a progestin, according to due tratment practice).
2. Women who have been hysterectomised
a) Medium potency estrogen only according to due treatment practice.

The patient's gynecologist will serve as the patient's consultant concerning choice of HRT, dosage and duration of treatment</interventions>
    <comparator>The patients randomized to follow-up only (no HRT) are not going to receive placebo, but should be advised about best available symptomatic treatment without hormones 
</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The aim of the present study is to investigate in women with radically treated in situ, stage I or early stage II breast cancer, if the use of hormone replacement therapy (HRT for menopausal symptoms) is safe concerning risk of breast cancer recurrence. </outcome>
      <timepoint>Patients will be assessed by the clinician for progression of disease and side effects of treatment at biyearly visits during the first three years as a minimum and yearly thereafter for a minimum of 5 years.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Secondary aims are to look at differences between the two study arms concerning quality of life and risk of
breast cancer death. After the main analyses, a study organisation will be built to decide if it is feasible and clinically meaningful to follow the two patient cohorts over a long time by means of record linkage and questionnaires concerning the cumulative incidence of myocardial infarction, cerebral stroke and fracture of the spine or hip. It is to be noted that the postulated study entails that most women will have a relatively short exposure to exogenous estrogens and the effect on cardiovascular events and osteoporosis will probably be small if any.</outcome>
      <timepoint>Patients will be assessed by the clinician for progression of disease at biyearly visits during the first three years as a minimum and yearly thereafter for a minimum of 5 years.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Health Questionnaires</outcome>
      <timepoint>Completed by the patient at years 1 and 3.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion and Exclusion Criteria- The study is directed only towards patients with climacteric symptoms, however, the degree of symptoms necessary for entering the trial is not specified in this protocol. Both perimenopausal and menopausal women are accepted into the trial.- The patient shall have been treated previously on one occasion for a breast cancer in stages cancer in situ to stage II of disease, but with four or fewer involved axillary nodes if nodal status and number of nodes investigated known. Stages are defined by UICC pTNM staging.- The patient shall be free from recurrences of breast cancer. It is recommended that the patient has a recent (within three months) mammogram.- Both hormonal receptor positive and negative patients are accepted into the study. Patients with unknown receptor status are also accepted. It is strongly recommended that the responsible clinician tries to find primary data for hormone receptor status and reports these on the study form.- All primary treatment shall be finished including cytotoxic therapy and radiotherapy. Adjuvant tamoxifen and toremifene treatment is however accepted. Patients who have previously been randomized into trials comparing the effects ofchemotherapy and castration in premenopausal women are not accepted into the trial. Patients who have previously been treated with HRT after their breast cancer diagnosis or who are on hormonal breast cancer treatments other than tamoxifen or toremifene cannot be randomized.- Patients who have been treated with HRT before their breast cancer diagnosis can be randomized into the trial to continue with HRT or to stop treatment. To be eligible, the women shall have stopped her previous HRT at the latest one month after diagnosis and have been without treatment for at least 3 months. The HRT to be recommended will be the one proposed for the hormonal treatment arm in this protocol.- The patient shall not have had any other cancer, including metachronous breast cancer (patients with synchronous breast cancer are however eligible, stage is judged by the tumour with the highest stage). Previous treatment for basalioma of the skin or cervical cancer in situ is however permitted. - The patient shall be without contraindications for hormonal treatment.- The patient shall be willing to participate in the trial.- The patient shall not have any other serious disease strongly limiting life expectancy and/or likelihood to comply with treatment.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria is above in the 'inclusion' criteria section.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central Randomisation by phone or fax</concealment>
    <sequence>Computer generated stratified blocks</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>N/A</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/03/1997</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1300</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Regional Oncologic Centre, Sweden</primarysponsorname>
    <primarysponsoraddress>to be confirmed</primarysponsoraddress>
    <primarysponsorcountry>Sweden</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Australian New Zealand Breast Cancer Trials Group</fundingname>
      <fundingaddress>trial now complete. No further information will be added due to time constraints.</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>International Breast Cancer Study Group</sponsorname>
      <sponsoraddress>trial now complete. No further information will be added due to time constraints.</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>The Australian New Zealand Breast Cancer Trials Group</sponsorname>
      <sponsoraddress>trial now complete. No further information will be added due to time constraints.</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Menopausal symptoms are common in women treated for early breast cancer.  Hormone replacement therapy (HRT) is very effective at relieving menopausal symptoms, but we do not know if HRT is helpful or harmful for women who have had breast cancer.  This trial will determine the effects of HRT in women who have been treated for early breast cancer.  The trial aims to include 1300 women from around the world who will be treated with either HRT or the best non-hormonal alternative treatment while being closely monitored by their cancer specialists and gynaecologist.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Border Medical Oncology</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Geelong Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mount Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mater Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Newcastle Mater Misericordiae Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal hospital for Women</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Womenâ€™s Hospital Melbourne</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor John F Forbes</name>
      <address>ANZ BCTG Operations Office
Department of Surgical Oncology
Locked Bag 7
Hunter Region Mail Centre  NSW  2310</address>
      <phone>+61 2 49 85 0113</phone>
      <fax>+61 2 49 60 1539</fax>
      <email>enquiries@anzbctg.newcastle.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Administrative Officer, Data Management</name>
      <address>ANZ BCTG Operations Office
Department of Surgical Oncology
Locked Bag 7
Hunter Region Mail Centre NSW 2310</address>
      <phone>+ 61 2 4985 0166</phone>
      <fax>+ 61 2 4985 0141</fax>
      <email>enquiries@anzbctg.newcastle.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>